Patents by Inventor Jorg Ogorka

Jorg Ogorka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Melt-processed imatinib dosage form
    Patent number: 8841303
    Abstract: The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: September 23, 2014
    Assignees: Abbvie Deutschland GmbH & Co. KG, Novartis AG
    Inventors: Jörg Breitenbach, Norbert Steiger, Harald Hach, Ulrich Westedt, Martin Knobloch, Ralf Altenburger, Nicoletta Loggia, Jörg Ogorka
  • HIGH DRUG LOAD TABLET
    Publication number: 20120177737
    Abstract: The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula or a pharmaceutically acceptable salt thereof in an amount from about 30% to 80% in weight of the active moiety based on the total weight of the tablet.
    Type: Application
    Filed: March 19, 2012
    Publication date: July 12, 2012
    Inventors: Christian-Peter LUFTENSTEINER, Jean-Claude BIANCHI, Jörg OGORKA, Oskar KALB
  • ORAL CONTROLLED RELEASE FORMULATIONS
    Publication number: 20110038897
    Abstract: This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behaviour problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy.
    Type: Application
    Filed: October 27, 2010
    Publication date: February 17, 2011
    Inventors: Rajen SHAH, Satish Chandra Khanna, Oskar Kalb, Jörg Ogorka
  • MELT-PROCESSED IMATINIB DOSAGE FORM
    Publication number: 20100240672
    Abstract: The invention provides a dosage form, comprising a melt-processed mixture of (a) a pharmaceutically effective amount of imatinib or a salt thereof, (b) at least one polymeric binder, and (c) at least one pharmaceutically acceptable non-ionic surfactant. The invention provides imatinib dosage forms with high drug loading which can be prepared in a simple and efficient manner, imatinib dosage forms from which the active principle is released in an essentially pH-independent fashion, and extended release imatinib dosage forms.
    Type: Application
    Filed: November 8, 2004
    Publication date: September 23, 2010
    Applicants: ABBOTT GMBH & CO. KG, NOVARTIS AG
    Inventors: Jorg Breitenbach, Norbert Steiger, Harald Hach, Ulrich Westedt, Martin Knobloch, Ralf Altenburger, Nicoletta Loggia, Jörg Ogorka
  • HIGH DRUG LOAD TABLET
    Publication number: 20100203133
    Abstract: The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula or a pharmaceutically acceptable salt thereof in an amount from about 30% to 80% in weight of the active moiety based on the total weight of the tablet.
    Type: Application
    Filed: April 21, 2010
    Publication date: August 12, 2010
    Applicant: NOVARTIS AG
    Inventors: Christian-Peter LUFTENSTEINER, Jean-Claude Bianchi, Jörg Ogorka, Oskar Kalb
  • PHARMACEUTICAL COMPOSITION COMPRISING A CAMPOTHECIN DERIVATIVE
    Publication number: 20100166843
    Abstract: The present invention relates to pharmaceutical compositions comprising a topoisomerase I inhibitor including, but not limited to, a camptothecin derivative.
    Type: Application
    Filed: January 30, 2008
    Publication date: July 1, 2010
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Giancarlo Francese, Jörg Ogorka, Jia-ai Zhang
  • Liposome Compositions
    Publication number: 20080286352
    Abstract: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes and/or liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components. After a desired liposome biodistribution is achieved, the affinity agent binds to the target surface and helps internalize the liposomes.
    Type: Application
    Filed: August 31, 2006
    Publication date: November 20, 2008
    Inventors: Saran Kumar, Wenlei Jiang, Jorg Ogorka, Jia-ai Zhang
  • Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin
    Publication number: 20080206322
    Abstract: The present invention relates to a novel composition, e.g. of mycophenolic acid, a salt or a prodrug thereof, in a modified release form.
    Type: Application
    Filed: August 29, 2005
    Publication date: August 28, 2008
    Applicant: NOVARTIS AG
    Inventors: Dieter Becker, Jutta Beyer, Janez Kerc, Andrea Kramer, Nicoletta Loggia, Chirstian-Peter Luftensteiner, Jorg Ogorka
  • Sustained release oral formulations
    Publication number: 20070053982
    Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
    Type: Application
    Filed: November 3, 2006
    Publication date: March 8, 2007
    Inventors: Jorg Ogorka, Oskar Kalb, Rajen Shah, Satish Khanna
  • Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin
    Publication number: 20070036857
    Abstract: The present invention relates to a novel composition of mycophenolic acid, a salt or a prodrug thereof and to a fixed combination of mycophenolic acid, a salt or a prodrug thereof and rapamycin or a rapamycin derivative.
    Type: Application
    Filed: October 1, 2004
    Publication date: February 15, 2007
    Inventors: Dieter Becker, Carsten Burger, Gilles Feutren, Patrice Guitard, Andrea Kramer, Nicoletta Loggia, Christian-Peter Luftensteiner, Jorg Ogorka, Harald Ottinger
  • Oral controlled release formulations
    Publication number: 20060246101
    Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigmine, in a time-controlled manner.
    Type: Application
    Filed: June 30, 2006
    Publication date: November 2, 2006
    Inventors: Rajen Shah, Satish Khanna, Oskar Kalb, Jorg Ogorka
  • High drug load tablet
    Publication number: 20050267125
    Abstract: The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula or a pharmaceutically acceptable salt thereof in an amount from about 30% to 80% in weight of the active moiety based on the total weight of the tablet.
    Type: Application
    Filed: April 22, 2003
    Publication date: December 1, 2005
    Inventors: Christian-Peter Luftensteiner, Jean-Claude Bianchi, Jorg Ogorka, Oskar Kalb
  • Compositions comprising hmg-coa reductase inhibitor
    Publication number: 20050239884
    Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising as active ingredient an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, said composition comprising an inner phase (internal) and an outer phase (external), wherein at least the outer phase comprises at least one matrix former.
    Type: Application
    Filed: July 24, 2003
    Publication date: October 27, 2005
    Inventors: Andreas Meyer, Jorg Ogorka, Sabine Desset-Brethes
  • Sustained release oral formulations
    Publication number: 20050175706
    Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigmine, in a time-controlled manner.
    Type: Application
    Filed: April 14, 2005
    Publication date: August 11, 2005
    Inventors: Jorg Ogorka, Oskar Kalb, Rajen Shah, Satish Khanna
  • Sustained release oral formulations
    Publication number: 20030203025
    Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
    Type: Application
    Filed: March 31, 2003
    Publication date: October 30, 2003
    Inventors: Jorg Ogorka, Oskar Kalb, Rajen Shah, Satish Chandra Khanna
  • Controlled release oral compositions comprising rivastigmine
    Patent number: 6565883
    Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: May 20, 2003
    Assignee: Novartis AG
    Inventors: Jörg Ogorka, Oskar Kalb, Rajen Shah, Satish Chandra Khanna
  • Sustained release oral formulations
    Publication number: 20030039692
    Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
    Type: Application
    Filed: April 8, 2002
    Publication date: February 27, 2003
    Inventors: Jorg Ogorka, Oskar Kalb, Rajen Shah, Satish C. Khanna
  • Sustained release oral formulations
    Publication number: 20010033866
    Abstract: Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
    Type: Application
    Filed: March 27, 2001
    Publication date: October 25, 2001
    Inventors: Jorg Ogorka, Oskar Kalb, Rajen Shah, Satish Chandra Khanna